MARKET

RIGL

RIGL

Rigel Pharmaceuticals Inc
NASDAQ
1.140
+0.080
+7.55%
After Hours: 1.120 -0.02 -1.75% 18:02 11/30 EST
OPEN
1.090
PREV CLOSE
1.060
HIGH
1.145
LOW
1.065
VOLUME
956.00K
TURNOVER
0
52 WEEK HIGH
2.040
52 WEEK LOW
0.6700
MARKET CAP
198.78M
P/E (TTM)
-8.2251
1D
5D
1M
3M
1Y
5Y
Rigel Pharmaceuticals Inc: Current report
Press release · 14h ago
Weekly Report: what happened at RIGL last week (1120-1124)?
Weekly Report · 3d ago
Best Momentum Stocks to Buy for November 22nd
NASDAQ · 11/22 15:00
New Strong Buy Stocks for November 22nd
NASDAQ · 11/22 11:23
Weekly Report: what happened at RIGL last week (1113-1117)?
Weekly Report · 11/20 09:04
Rigel Pharma To Present At The Jefferies London Healthcare Conference; Webcast At 10:30 AM ET
NASDAQ · 11/14 14:29
Weekly Report: what happened at RIGL last week (1106-1110)?
Weekly Report · 11/13 09:04
Holding Steady: A Detailed Analysis of Rigel Pharmaceuticals’ Performance and Prospects
TipRanks · 11/09 18:25
More
About RIGL
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in discovering, developing and providing therapies that improve the lives of patients with hematologic disorders and cancer. The Company's lead product, TAVALISSE (fostamatinib disodium hexahydrate) tablets, the spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia (ITP). Its product also includes REZLIDHIA (olutasidenib) capsules, which are for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. Its other clinical programs include its interleukin receptor-associated kinase (IRAK) inhibitor program and a receptor-interacting serine/threonine-protein kinase (RIPK1) inhibitor program in clinical development. In addition, it has product candidates in clinical development with partners BerGenBio ASA (BerGenBio) and Daiichi Sankyo (Daiichi).

Webull offers Rigel Pharmaceuticals Inc stock information, including NASDAQ: RIGL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RIGL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RIGL stock methods without spending real money on the virtual paper trading platform.